Vericel Co. (NASDAQ:VCEL) Holdings Raised by Comerica Bank

Comerica Bank lifted its position in shares of Vericel Co. (NASDAQ:VCEL) by 0.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 193,610 shares of the biotechnology company’s stock after acquiring an additional 1,635 shares during the quarter. Comerica Bank’s holdings in Vericel were worth $10,631,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in VCEL. Arcadia Investment Management Corp MI acquired a new stake in shares of Vericel during the fourth quarter worth $48,000. Smartleaf Asset Management LLC raised its stake in Vericel by 511.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 1,058 shares during the period. Meeder Asset Management Inc. lifted its holdings in Vericel by 8.4% in the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 183 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 2,240 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Vericel by 82.5% during the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,224 shares during the last quarter.

Vericel Stock Up 2.7 %

Shares of Vericel stock opened at $38.95 on Friday. The business has a fifty day simple moving average of $44.24 and a 200-day simple moving average of $51.18. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of 649.27 and a beta of 1.61. Vericel Co. has a fifty-two week low of $37.39 and a fifty-two week high of $63.00.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on VCEL shares. Truist Financial reduced their price objective on Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday, April 11th. Stephens restated an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, February 28th. Canaccord Genuity Group upped their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.86.

Insider Buying and Selling at Vericel

In other Vericel news, insider Jonathan Siegal sold 1,092 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total value of $67,693.08. Following the transaction, the insider now owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. This represents a 47.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 26,592 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $45.78, for a total value of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares of the company’s stock, valued at $11,902,662.66. This trade represents a 9.28 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 55,034 shares of company stock valued at $2,482,291. 5.20% of the stock is owned by insiders.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.